SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ebola Outbreak 2014 - News, Updates and Related Investments
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: statesidereport8/25/2014 9:03:15 AM
   of 608
 
So ZMapp isn't the cure.........next up TKM?

Liberian doctor dies after receiving experimental Ebola drug
BY JONATHAN PAYE-LAYLEH
Associated PressAugust 25, 2014

MONROVIA, LIBERIA — A Liberian doctor who was among three Africans to receive an experimental Ebola drug has died, the country’s information minister said Monday.

Dr. Abraham Borbor, the deputy chief medical doctor at the country’s largest hospital, had been among three Liberians, and the first Africans, who received the drug, ZMapp. Two Americans received the untested drug and survived. A Spaniard infected with Ebola received the treatment but died. There was no update given on the two other Liberians who took doses of the drug.

Borbor “was showing signs of improvement but yesterday he took a turn for the worse,” Information Minister Lewis Brown told The Associated Press. It wasn’t clear if he died late Sunday or on Monday.

Ebola has killed more than 1,400 people across West Africa. There is no proven vaccine or cure for the disease that can cause a grisly death with bleeding from the eyes, mouth and ears.

The virus can only be transmitted through direct contact with the bodily fluids of the sick or from touching victims’ bodies, leaving doctors and other health care workers most vulnerable to contracting it.

Only five people in the world are known to have received ZMapp. The small supply is now said to be exhausted, and it is expected to be months before more can be produced by its U.S. maker.

Health experts caution that the drug had never been tested in humans before and it was unclear whether it works. They note there is a huge gap between the treatment the two Americans got at an Atlanta hospital, where five infectious disease experts and 21 nurses provided rigorous care, and West Africa, where even such basics as sterile fluids can be in short supply.

Read more here: heraldonline.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News